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Species Differences with Regard to the Therapeutic
Activity, Toxicity, and Carcinogenicity of Xeno-
biotics. RICHARD H. ADAMSON, Laboratory of
Chemical Pharmacology, National Cancer In-
stititte, National Institiutes ofHealth, Bethesda,
Maryland 20014
Species differences with regard to the therapeutic activity, tox-
icity and carcinogenicity of various xenobiotics may be attrib-
uted to many factors which have been classified as internal en-
vironmental factors, external environmental factors, or xenobio-
tic administration factors [Dearborn, E. H., Fed. Proc. 26: 1075
(1967)]. Examples ofinternal environmental factors are sex, age,
weight, nutritional state, and pregnancy, examples of external
environmental factors are temperature, sound, time of day, or
ambient atmosphere composition; examples of drug administra-
tion factors are route and rate ofadministration, particle size, or
vehicle in which administered. Even when these types offactors
are properly controlled, species exhibit differences with regards
to their response to xenobiotics. Among the reasons for these
differences are: differences in xenobiotic disposition, i.e., ab-
sorption, distribution, metabolism and excretion (Adamson,
R. H., and Davis, D. S. In: International Encyclopedia of
Pharmacology and Toxicology, M. J. Michelson, Ed., Pergam6n
Press, Oxford-New York, 1973, Section 85, Chapt. 9, pp. 851-
911); anatomical and physiological differences; differences in
binding to plasma protein and at the receptor site; interaction
with virus, especially oncogenic virus present ininbreed species;
differences with regard to DNA repair and differences in amount
ofrepair enzymes; and differences in the diet and the amount of
nucleophils in the diet which may protect against electrophilic
attack and thereby modify the potential clastogenic, mutagenic,
teratogenic and carcinogenic potential of the xenobiotic.
Examples of these differences are given when possible and
areas in which little data exists and research is needed is also
stressed. In particular, it is suggested that, in species in which
xenobiotics exhibit only weak carcinogenic effects as compared
to untreated control animals, the potential role of interaction
which "C" type particles must be examined, and that these data
cannot always be extrapolated to humans.
Chemokinetics. DANIEL S. ZAHARKO, Laboratory of
Chemical Pharmacology, National Cancer In-
stitute, Bethesda, Maryland 20014
In order to extrapolate results of laboratory animal data to
man with reasonable expectations ofvalidity, certain factual sci-
entific information must be known. Scientists and regulatory
agencies have primarily used dose-effect relationships in animals
as the basis forextrapolation toexpected effects in man. Such data
with arbitrary "safety" factors included most often provide the
estimated safe level ofexposure. There are other kinds ofinfor-
mation which can be used to increase predictive reliability. If a
substance is toxic to an animal species it is important to under-
stand the biochemical mechanism by which this toxicity is
created. Does the substance compete with normal substrates for
an enzyme or bind to an enzyme? Does the substrate react with
essential macromolecules (nucleic acids, membranes or cyto-
plasmic organ, by inducing an enzyme or by chelation of an
essential trace metal)? These examples are just a few of many
possible ones to illustrate the potential variety of mechanisms.
Knowledge ofthe mechanism ofaction alone however is farfrom
sufficient to predict toxic effects within a species at different
doses or from species to species. This has been thoroughly dem-
onstrated with antimetabolites in cancer research (Zaharko, D. S.
In: Pharmacological Basis ofCancer Chemotherapy, Williams &
Williams, Baltimore, 1975, p. 69).
Another important consideration is the chemokinetic behavior
of the substance within an animal. Such information with many
drugs has been collected and several important principles have
been elucidated. The importance of proper scaling from species
to species is one factor which is frequently neglected. There are
still scientific reports which criticize toxicity studies in small
animals as being nonrelevant to man because ofthe much larger
dose (usually expressed in mg/kg) used in the small experimental
animal study. There is still a lack of appreciation for the higher
metabolic rates and higher clearances that generally exist in ex-
perimental animals as compared to man. (Schmidt-Nielsen,'K.
How Animals Work. Cambridge Univ. Press, New York, 1972,
p. 54). These factors affect the rate of delivery of substances to
tissues in intact animals. Other factors affecting delivery to in-
tracellular compartments are blood flow, mixing volumes, mem-
brane permeability and binding. Computer models can simulate
such factors and give insight concerning their relative signifi-
cance in determining concentration and exposure time at the
actual site. [Lutz, R. J., et al. J. Pharmacokin. Biopharm. 3: 77
(1975)].
If concentrations at the active site can be predicted and the
biochemical mechanism is known, then ways of counteracting
the effect may be considered. When environmental exposure is
inevitable or accidental, use of another substance to protect
against toxicity might be effective.
Variability of Risk Extrapolation in Dose-Response
Experiments. CHARLES C. BROWN, National In-
stitutes ofHealth, Bethesda, Maryland 20014
The number ofchemicals in the environment which are found
tobe associated withcarcinogenic activity isincreasing at arapid
pace. For the carcinogens which cannot be easily eliminated, an
estimate ofthe risk to the population should be made before any
decisions can be taken. Since information on human populations
exposed to the chemical is not available in most cases, data from
animal experiments conducted at high doses are used to estimate
the cancer risk at low dose levels.
The estimation of this low dose risk attributable to the agent
under test consists ofextrapolation from the observable dose-re-
sponse relationship at high dose levels to doses close to zero.
This extrapolation procedure must, by necessity, be based on
some assumption concerning the dose-response relationship at
these lower dose levels. This assumption is generally arbitrary,
since little is known about the carcinogenic process in this low
dose region. Because of this lack of knowledge, the current ap-
proaches to risk estimation have tended to be conservative in
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practice in that there is no measure of the variability of the esti-
mated risks orextrapolated "safe" dose levels. Everyone agrees
that these methods lead to conservative answers, and, from the
aspect ofpublic safety, this is a reasonable goal. Ifpublic safety
is ofpredominant concern, however, then the most conservative
approach would simply be to ban the use of all such chemicals
shown to be carcinogens and the concern overestimating "safe"
dose levels would be a moot question. Therefore, ifwe are going
to accept extrapolation as a necessary evil, the only prudent
decisions can be made on risk estimation procedures that are not
completely arbitrary and assumption-dependent but include
some measure of the uncertainties inherent in these estimates.
The purpose ofthis paper is to suggest methods ofmeasuring the
two components of this uncertainty, variability due to sampling
and due to dependency on a specific dose-response model.
Two techniques are proposed for measuring these components
of variation, a relative likelihood analysis to measure sampling
variation combined with ageneral multiparameter dose-response
model to measure the model-specific variation. Experimental
data on dimethylnitrosamine fed to female rats are used to illus-
trate these techniques and to point out the practical difficulties of
fitting models to dose-response data. Threshold models and the
difficulty in distinguishing between threshold and nonthreshold
models are also discussed.
Qualitative Extrapolation from Laboratory Assay to
Humans as Seen Through the Carcinogenicity,
Mutagenicity or Teratogenicity ofVinyl Chloride,
and Anesthetic Gases. JOSEPH K. WAGONER, Oc-
cupational Safety and Health Administration,
Washington, D. C. 20210, and PETER F. IN-
FANTE, Industry-Wide Studies Branch, Division
of Surveillance Hazard Evaluation Field
Studies, National Institute for Occupational
Safety and Centerfor Disease Control, Cincin-
nati, Ohio 45226.
Historically, most toxic agents which have been documented
by observations both in humans and experimental animals, were
first identified post hoc in man, through fortuitous clinical
impressions, explosive surfacing of rare diseases or structured
epidemiologic investigations. Subsequently, these observations
were confirmed repeatedly by animal bioassay over a wide range
of doses and species. Certainly this pathway has been the case
for most identified carcinogenic or embryotoxic agents. Such is
true for soot, tar, aromatic amines, asbestos, chromates, nickel
carbonyl, lead, thalidomide, and many other agents. This high
concordance oftoxicity between man and animal forthese agents
has suggested to many the value ofscreening ofchemicals prior
to their introduction into the environment. This same high con-
cordance has been argued by others to be an artifact arisingfrom
tests of chemicals already known to be toxic to man.
Recent observations, however, with regard to DES, BCME,
vinyl chloride and anesthetic agents, now demonstrate and for-
tify the unbiased value ofanimal bioassay and other short-term in
vitro test systems as powerful qualitative predictive tools for
assessing the spectrum of carcinogenic, mutagenic and
teratogenic hazards to man. Evidence for the carcinogenicity and
mutagenicity of vinyl chloride is presented going from the
laboratory assay to observation in man. The teratogenicity of
anesthetic agents is presented, first in animals and then among
humans.
Dose-Response Relationships in Radiation Car-
cinogenesis. FREDERICK P. Li, Boston Field
Studies Section, Epidemiology Branch, National
Cancer Institute, Boston, Massachusetts 02115
Extrapolation of carcinogenesis data from intensely exposed
persons to populations exposed at low levels is often complicated
by problems of individual susceptibility, inaccurate dose mea-
surement, long latency, and inadequate numbers for study. In
this discussion, findings are presented of two recent studies of
patients given therapeutic irradiation in childhood. One group of
414 persons was intensely treated, and developed excess can-
cers. The absolute risk was 1.8 cancers in exposed tissues per
million person-year-rads. The relative risk was 20-fold above
expectation. In contrast, the second series of4,746 patients re-
ceived much lower doses of irradiation, and showed no increase
in cancer mortality rates. The studies suggest a dose-response
relationship, but the two series differ for many risk factors other
than the nominal dose ofradiation. Data from the literature also
show evidence of dose-response, despite the diverse conditions
of exposure to ionizing radiation. For leukemia, studies of
atomic bomb survivors and of irradiated spondylitis patients
show increasing risk of the neoplasm with increase in dose. For
the thyroid gland, the frequency of nodularity, including car-
cinoma, rises proportionally with dose. In patients exposed to
several radionuclides, a dose-response is also demonstrable.
These and other studies constitute the data resource from which
judgements are made regarding the hazards to the general popu-
lation of much lower doses of radiation. A number of reports
suggest a linear dose-response effect for carcinogenesis under
conditions of exposure to very high levels of radiation at a high
dose rate. However, in several studies, a nonlinear model is also
possible. With either model, dose-response relationship beyond
the range of measurement is based on extrapolation. There are
biologic reasons to suspect that at high doses of ionizing
radiation lethality predominates oncogenic effects, so that fewer
tumors are produced. At low doses cells may repair radia-
tion injuries, so that the carcinogenic effect is also diminished.
With the uncertainties ofestimating risk of cancer following ex-
posure at low doses, safety recommendations are often made on
pragmatic grounds that take into account cost versus benefit
considerations. Forradiation carcinogenesis, linear interpolation
into the low-dose range appears to be a prudent method for de-
riving approximate numerical estimates of cancer risk for man.
However, risk estimates are not inviolable, and should be mod-
ified as relevant new data are accumulated.
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